Story

Huadong Medicine Subsidiary Sinclair Pharma Gains EU Approval for New Aesthetic Injectable

ENTHMSVIIDZHZH-TWJAKOHI
Aug 9, 20261 min read
Huadong Medicine Subsidiary Sinclair Pharma Gains EU Approval for New Aesthetic Injectable
Text size
Background

Huadong Medicine Co., Ltd. (000963.SZ) announced that its wholly-owned UK subsidiary, Sinclair Pharma Limited, has received European Union market approval for a new medical aesthetic injectable. The certification allows the company to begin marketing and selling the product across the EU.

Key Certification Secured

According to a company filing, Sinclair's injectable carboxymethyl chitosan solution, designated KIO015, has successfully obtained the MDR CE certification. This mark confirms the product's compliance with the EU's comprehensive Medical Device Regulation, a critical requirement for market access.

The product, which will be sold under the brand name Kytogen® Defend, is described by the company as the world's first and currently only innovative aesthetic injectable formulated with non-animal-derived chitosan. This patented ingredient differentiates it from other products in the aesthetics market.

Market and Financial Implications

Securing the CE mark provides Sinclair with the necessary qualifications to launch Kytogen® Defend in the European Union and other markets that recognize the certification. This expands the company's commercial footprint in the competitive global aesthetics sector.

Sample IUX Markets – In-articleAd

Despite the strategic importance of the approval, Huadong Medicine stated that it does not expect the development to have a significant impact on its current financial results. The company did note, however, that it anticipates a positive contribution to future performance as sales are established.

Key details on the product's current status include:

  • Approval: Has received the EU MDR CE mark.
  • Revenue: Has not yet generated any sales revenue.
  • Domestic Status: Has not yet obtained medical device registration in China.

Strategic Context

The approval marks a step forward in Huadong Medicine's strategy to expand its international presence in medical aesthetics, an effort significantly bolstered by its acquisition of UK-based Sinclair. The launch of a novel, patented product like Kytogen® Defend strengthens Sinclair's portfolio and its competitive position in the European market.

Read next

More on Stocks
Back to latest news

LATEST